Nagoya University: New cyclic disulfide lipids deliver mRNA five times more effectively for cancer treatment University of Ottawa: Development of nano-sized delivery agents with therapeutic potential beyond messenger function University of Pennsylvania: Chemical modification of ionizable lipids reduces inflammation and boosts mRNA therapeutic effectiveness Academic Journals: Multiple publications on circular guide RNA engineering, CRISPR-Cas13d systems, and advanced LNP ch

We’re excited to announce that PreciGenome will be exhibiting at the CRS 2025 Annual Meeting & Exposition! Join us at booth #406 to discover our latest innovations in lipid nanoparticle (LNP) technology. What we offer: Advanced LNP synthesis instruments for efficient and reproducible nanoparticle production High-quality LNP reagents to support your research and development Comprehensive CRO services tailored for your LNP and drug delivery projects Connect with our

AbbVie: acquires Capstan Therapeutics for up to $2.1 billion, adding targeted LNP (tLNP) in vivo CAR-T technology to its immunology pipeline. CRISPR Therapeutics: Phase 1 data show LNP-delivered CRISPR candidate CTX310 cuts triglycerides and LDL by up to 82% and 86%, respectively. University of Pennsylvania–Genevant (Nature Nanotechnology): PEG-lipid ratio and phospholipid choice fine-tune mRNA-LNP adjuvanticity, guiding vaccine design. Ludwig-Maximilians-Universität Münch

Eli Lilly: Acquired Verve Therapeutics for up to $1.3 billion to advance LNP-based gene editing therapies for cardiovascular disease. Genprex: Presented research on non-viral diabetes gene therapy using lipid nanoparticle delivery system at the American Diabetes Association conference. SNS Insider: Published market report projecting lipid nanoparticles market to reach $2.89 billion by 2032, driven by mRNA technology advances. Nature Nanotechnology: Published study on tailo

Cornell University: Developed PEG-free "stealth" LNPs to reduce immune responses in mRNA vaccines. University of Hawaiʻi/Sungkyunkwan University: Created neutrophil-targeted LNPs to mitigate COVID-19 lung damage. Moderna: Received FDA approval for next-gen COVID-19 vaccine (mNEXSPIKE) using refrigerated LNPs. CRISPR Therapeutics: Reported positive Phase 1 data for LNP-delivered ANGPTL3 gene-editing therapy. University of Pennsylvania: Enhanced T-cell responses in mRNA vac

We're proud to share that the Mayo Clinic Florida’s new RNA Research Facility has chosen the PreciGenome NanoGenerator™ Flex-S as their...

Mana.bio: Presented new data demonstrating AI-driven safety model for lipid nanoparticle tolerability to enhance RNA medicine. Grit Biotechnology: Presented scientific breakthroughs at ASGCT 2025 including LNP-mediated CRISPR/Cas9 gene editing for enhancing tumor-infiltrating lymphocytes. Generation Bio: Reported business highlights including advancement of their cell-targeted lipid nanoparticle (ctLNP) technology for siRNA delivery. Aera Therapeutics: Shifted focus

StatNano/Grand View Research: A new market report forecasts the global lipid nanoparticle market to reach $1.54 billion by 2030, growing at a CAGR of 13.64%, driven by increased demand for innovative drug delivery solutions. SyVento BioTech: SyVento BioTech participates in the World Vaccine Congress in Washington, D.C., showcasing their expertise in lipid-based nanocarriers and LNP technology for pharmaceutical products including RNA-based drug products. Arbor Biotechno